Entrada Therapeutics, Inc. (TRDA) News
Filter TRDA News Items
TRDA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TRDA News Highlights
- For TRDA, its 30 day story count is now at 20.
- Over the past 22 days, TRDA's stories per day has been in a clear uptrend, growing by about 0.09 per day.
- The most mentioned tickers in articles about TRDA are III, LUNG and DRUG.
Latest TRDA News From Around the Web
Below are the latest news stories about ENTRADA THERAPEUTICS INC that investors may wish to consider to help them evaluate TRDA as an investment opportunity.
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca OnbodyThe FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. |
Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 SharesKory Wentworth, the CFO of Entrada Therapeutics Inc (NASDAQ:TRDA), executed a sale of 12,500 shares in the company on December 26, 2023, according to a recent SEC Filing. |
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer CandidateThe FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises. |
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive CandidiasisCidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%. |
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer ProgramSanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint. |
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Studyargenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls. |
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review TagThe FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024. |
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAAThe CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise. |
Invivyd (IVVD) Surges on Positive Data From COVID-19 StudyInvivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news. |